Leukemia, Acute Myeloid disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

AML MCID: LKM061 MIFTS: 81	Leukemia, Acute Myeloid (AML) Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid ⁵⁸ ³⁹

Acute Myeloid Leukemia ³⁹ ¹² ⁷⁷ ⁵⁴ ⁷⁶ ³⁸ ³⁰ ⁶ ⁴⁴ ¹⁵ ¹⁷

Leukemia, Acute Myelogenous ⁵⁸ ⁷⁶ ¹³ ⁴¹

Acute Myelogenous Leukemia ¹² ⁷⁷ ⁵⁴ ¹⁵

Acute Undifferentiated Leukemia ⁶⁰ ⁵⁶ ⁷⁴

Acute Myeloblastic Leukemia ¹² ⁷⁷ ⁷⁶

Leukemia, Acute Myeloid, Susceptibility to ⁵⁸ ⁶

Leukemia, Myelocytic, Acute ¹² ⁷⁴

Acute Myelocytic Leukemia ⁷⁷ ⁷⁶

Leukemia, Myeloid, Acute ⁴⁵ ⁴¹

Aml ⁵⁸ ⁷⁶

Acute Myeloid Leukaemia with Myelodysplasia-Related Features ⁶⁰

Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 ⁶⁰

Leukemia, Acute Myeloid, Reduced Survival in, Somatic ⁵⁸

Acute Myeloid Leukemia with Cebpa Somatic Mutations ⁶⁰

Acute Myeloid Leukemia with Multilineage Dysplasia ⁶⁰

Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic ⁵⁸

Aml with Myelodysplasia-Related Features ⁶⁰

Pure Familial Acute Myeloid Leukemia ⁶⁰

Leukemia, Acute Myeloid, Somatic ⁵⁸

Aml with Cebpa Somatic Mutations ⁶⁰

Inherited Acute Myeloid Leukemia ⁶⁰

Acute Non-Lymphoblastic Leukemia ⁷⁶

Acute Myeloid Leukemia, Somatic ⁵⁸

Aml with Multilineage Dysplasia ⁶⁰

Acute Non-Lymphocytic Leukemia ⁷⁶

Aml - Acute Myeloid Leukemia ¹²

Leukemia, Acute Myeloblastic ¹³

Acute Biphenotypic Leukemia ⁷⁴

Pure Familial Aml ⁶⁰

Inherited Aml ⁶⁰

Familial Aml ⁶⁰

Characteristics:

Orphanet epidemiological data:

⁶⁰

acute myeloid leukaemia with myelodysplasia-related features
Age of onset: Adult;

OMIM:

⁵⁸

Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations
many genes with somatic mutation

HPO:

³³

leukemia, acute myeloid:
Inheritance somatic mutation autosomal dominant inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴ ³⁵

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Leukaemia of unspecified cell type

Acute leukaemia of unspecified cell type

Myeloid leukaemia

Acute myeloblastic leukaemia [AML]

Acute myeloid leukaemia with 11q23-abnormality

Acute myeloid leukaemia with multilineage dysplasia

Orphanet: ⁶⁰

Rare haematological diseases

External Ids:

Disease Ontology ¹² DOID:9119

OMIM ⁵⁸ 601626

KEGG ³⁸ H00003

ICD9CM ³⁶ 205.0

MeSH ⁴⁵ D015470

NCIt ⁵¹ C27753 C3171

SNOMED-CT ⁶⁹ 17788007 91861009

ICD10 ³⁴ C92.0 C92.00 C92.6 more

ICD10 via Orphanet ³⁵ C92.0 C92.8 C95.0

UMLS via Orphanet ⁷⁵ C0280141 C0856823 C1292773

Orphanet ⁶⁰ ORPHA319465 ORPHA319480 ORPHA86845 more

MedGen ⁴³ C0023467 C3275959

SNOMED-CT via HPO ⁷⁰ 124975008 263681008 413443009

EFO ¹⁷ EFO_0000222

UMLS ⁷⁴ C0023464 C0023467 C0280141

Sources

Summaries for Leukemia, Acute Myeloid

MedlinePlus : ⁴⁴ Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to core binding factor acute myeloid leukemia and leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Folotyn and Ixempra have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute myeloid leukemia and Reduced mammosphere formation

Disease Ontology : ¹² A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : ⁵⁴ Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inheritedsyndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy.

UniProtKB/Swiss-Prot : ⁷⁶ Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : ⁷⁷ Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

Description from OMIM: 601626

Sources

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid	Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia	Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 732)

#	Related Disease	Score	Top Affiliating Genes
1	core binding factor acute myeloid leukemia	34.2	CEBPA FLT3 JAK2 KIT KRAS NRAS
2	leukemia	34.1	CEBPA CSF3R ETV6 FLT3 JAK2 KIT
3	acute myeloblastic leukemia with maturation	34.0	FLT3 KIT NPM1
4	cytogenetically normal acute myeloid leukemia	33.9	CEBPA FLT3 NPM1
5	acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)	33.7	ETV6 FLT3 KIT RUNX1
6	acute erythroid leukemia	33.6	CEBPA GATA2 JAK2 PICALM
7	acute leukemia	33.5	CEBPA ETV6 FLT3 JAK2 KIT MLLT10
8	acute myeloblastic leukemia without maturation	33.2	FLT3 NPM1
9	acute myeloid leukemia with t(8;21)(q22;q22) translocation	33.2	CEBPA FLT3 KIT RUNX1
10	myeloid leukemia	33.0	CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
11	lymphoid leukemia	31.6	ETV6 FLT3 JAK2
12	myeloid sarcoma	31.6	FLT3 KIT NPM1
13	acute promyelocytic leukemia	31.5	CEBPA CSF3R FLT3 NPM1 NRAS RUNX1
14	myelodysplastic syndrome	31.5	CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
15	acute t cell leukemia	31.3	LPP MLLT10 NUP214
16	chronic myelomonocytic leukemia	31.2	CSF3R DNMT3A ETV6 FLT3 JAK2 KIT
17	leukemia, acute lymphoblastic	31.1	ETV6 FLT3 PICALM RUNX1
18	precursor t-cell acute lymphoblastic leukemia	31.1	ETV6 FLT3 MLLT10 NUP214 PICALM
19	leukemia, chronic myeloid	31.1	CSF3R ETV6 FLT3 GATA2 JAK2 KIT
20	myeloma, multiple	31.0	JAK2 KIT KRAS NRAS
21	bone marrow cancer	30.9	CSF3R ETV6 FLT3 JAK2 KIT RUNX1
22	juvenile myelomonocytic leukemia	30.9	DNMT3A FLT3 JAK2 KRAS NRAS RUNX1
23	neutrophilia, hereditary	30.9	CSF3R FLT3 JAK2
24	aplastic anemia	30.9	CSF3R FLT3 GATA2 NRAS TERT
25	myelodysplastic myeloproliferative cancer	30.9	CSF3R JAK2 NRAS
26	atypical chronic myeloid leukemia	30.8	CSF3R JAK2 RUNX1
27	aleukemic leukemia cutis	30.8	FLT3 NPM1 RUNX1
28	8p11 myeloproliferative syndrome	30.8	FLT3 KIT RUNX1
29	subacute myeloid leukemia	30.7	FLT3 JAK2
30	familial acute myeloid leukemia with mutated cebpa	12.7
31	therapy related acute myeloid leukemia and myelodysplastic syndrome	12.4
32	cebpa-associated familial acute myeloid leukemia	12.4
33	aml with myelodysplasia-related features	12.1
34	megakaryocytic leukemia	11.9
35	acute monoblastic leukemia	11.9
36	acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)	11.5
37	acute myeloid leukemia with minimal differentiation	11.5
38	myelodysplastic syndrome with excess blasts	11.5
39	platelet disorder, familial, with associated myeloid malignancy	11.4
40	acute non lymphoblastic leukemia	11.4
41	shwachman-diamond syndrome 2	11.3
42	myeloproliferative/lymphoproliferative neoplasms, familial	11.3
43	erythroleukemia, familial	11.3
44	acute myeloid leukemia with t(9;11)(p22;q23)	11.3
45	acute myeloid leukemia with t(6;9)(p23;q34)	11.3
46	acute myeloid leukemia with npm1 somatic mutations	11.3
47	acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor	11.3
48	acute myeloid leukemia with t(8;16)(p11;p13) translocation	11.3
49	ataxia-pancytopenia syndrome	11.3
50	anemia, sideroblastic, 1	11.3

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:

Sources

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Human phenotypes related to Leukemia, Acute Myeloid:

³³

#	Description	HPO Frequency	HPO Source Accession
1	acute myeloid leukemia ³³		HP:0004808

Symptoms via clinical synopsis from OMIM:

⁵⁸

Hematology:
acute myelogenous leukemia (aml)

Clinical features from OMIM:

601626

UMLS symptoms related to Leukemia, Acute Myeloid:

angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.23	CEBPA CSF3R DNMT3A ETV6 KRAS NRAS

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

⁴⁷ (show all 16)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.48	CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
2	hematopoietic system	MP:0005397	10.34	CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
3	growth/size/body region	MP:0005378	10.32	CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
4	homeostasis/metabolism	MP:0005376	10.32	CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
5	mortality/aging	MP:0010768	10.32	CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
6	embryo	MP:0005380	10.31	DNMT3A ETV6 GATA2 JAK2 KIT KRAS
7	immune system	MP:0005387	10.27	CEBPA CSF3R DNMT3A ETV6 FLT3 JAK2
8	endocrine/exocrine gland	MP:0005379	10.26	CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
9	cardiovascular system	MP:0005385	10.16	CEBPA ETV6 GATA2 KIT KRAS NPM1
10	integument	MP:0010771	10.13	CEBPA CHIC2 ETV6 JAK2 KIT KRAS
11	liver/biliary system	MP:0005370	10.06	CEBPA GATA2 JAK2 KIT KRAS NPM1
12	neoplasm	MP:0002006	10.02	CEBPA ETV6 FLT3 JAK2 KIT KRAS
13	no phenotypic analysis	MP:0003012	9.86	CEBPA ETV6 FLT3 KIT KRAS NRAS
14	normal	MP:0002873	9.81	CEBPA ETV6 GATA2 JAK2 KIT KRAS
15	pigmentation	MP:0001186	9.35	CHIC2 KIT KRAS NRAS PICALM
16	reproductive system	MP:0005389	9.23	CEBPA DNMT3A GATA2 JAK2 KIT KRAS

Sources

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁹	Company	Approval Date
1	Folotyn ¹⁹ ⁵⁰	PRALATREXATE	Allos Therapeutics	September 2009
FDA Label: Folotyn Disease/s that Drug Treats:peripheral T-cell lymphoma Indications and Usage: ¹⁹ FOLOTYN is a folate analog metabolic inhibitor indicated for the treatment ofpatients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Thisindication is based on overall response rate. Clinical benefit such asimprovement in progression-free survival or overall survival has not beendemonstrated. (1) DrugBank Targets: ¹⁶ 1. Dihydrofolate reductase;2. Thymidylate synthase Mechanism of Action: ¹⁹ Target: dihydrofolate reductase Action: inhibitor FDA: Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also acompetitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition resultsin the depletion of thymidine and other biological molecules the synthesis of which depends on single carbontransfer.
2	Ixempra ¹⁹ ⁵⁰	IXABEPILONE	Bristol-Myers Squibb	October 2007
FDA Label: Ixempra Disease/s that Drug Treats:Breast cancer Indications and Usage: ¹⁹ IXEMPRA, a microtubule inhibitor, in combination with capecitabine isindicated for the treatment of metastatic or locally advanced breastcancer in patients after failure of an anthracycline and a taxane (1). IXEMPRA as monotherapy is indicated for the treatment of metastaticor locally advanced breast cancer in patients after failure of ananthracycline, a taxane, and capecitabine (1). DrugBank Targets: ¹⁶ 1. Tubulin beta-3 chain Mechanism of Action: ¹⁹ Target: Î²-tubulin subunits on microtubules Action: suppressor of dynamics FDA: Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directlyto Î²-tubulin subunits on microtubules, leading to suppression of microtubule dynamics.Ixabepilone suppresses the dynamic instability of Î±Î²-II and Î±Î²-III microtubules.Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepiloneblocks cells in the mitotic phase of the cell division cycle, leading to cell death.
3	Leukine ¹⁹	SARGRAMOSTIM	Immunex	on November 24, 1995/ November 1996
FDA Label: Leukine Disease/s that Drug Treats:transplantation/ replenishment of white blood cells, fungal infections Indications and Usage: ¹⁹ DrugBank Targets: ¹⁶ 1. Granulocyte-macrophage colony-stimulating factor receptor subunit alpha;2. Interleukin-3 receptor subunit alpha;3. Cytokine receptor common subunit beta;4. Syndecan-2;5. Bone marrow proteoglycan Mechanism of Action: ¹⁹ Target: - Action: - FDA: -
4	Mylotarg ¹⁹ ⁵⁰	GEMTUZUMAB OZOGAMICIN	Wyeth	May 2000
FDA Label: Mylotarg Disease/s that Drug Treats:Acute Myeloid Leukemia (AML) Indications and Usage: ¹⁹ Mylotarg is indicated for the treatment of patients with CD33 positive acute myeloid leukemia infirst relapse who are 60 years of age or older and who are not considered candidates for othercytotoxic chemotherapy. The safety and efficacy of Mylotarg in patients with poor performancestatus and organ dysfunction has not been established.The effectiveness of Mylotarg is based on OR rates (see CLINICAL STUDIES section). Thereare no controlled trials demonstrating a clinical benefit, such as improvement in disease-relatedsymptoms or increased survival, compared to any other treatment. DrugBank Targets: ¹⁶ 1. Myeloid cell surface antigen CD33;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c Mechanism of Action: ¹⁹ Target: CD33 antigen expressed byhematopoietic cells Action: binds to form complex that then causes a break in the DNA double strand FDA: Mylotarg is directed against the CD33 antigen expressed byhematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33antigen results in the formation of a complex that is internalized. Upon internalization, thecalicheamicin derivative is released inside the lysosomes of the myeloid cell. The releasedcalicheamicin derivative binds to DNA in the minor groove resulting in DNA double strandbreaks and cell death.Gemtuzumab ozogamicin is cytotoxic to the CD33 positive HL-60 human leukemia cell line.Gemtuzumab ozogamicin produces significant inhibition of colony formation in cultures of adultleukemic bone marrow cells. The cytotoxic effect on normal myeloid precursors leads tosubstantial myelosuppression, but this is reversible because pluripotent hematopoietic stem cellsare spared. In preclinical animal studies, gemtuzumab ozogamicin demonstrates antitumoreffects in the HL-60 human promyelocytic leukemia xenograft tumor in athymic mice.
5	Arcapta ¹⁹	INDACATEROL MALEATE	Novartis	July 2011
FDA Label: Arcapta Disease/s that Drug Treats:airflow obstruction resulting from chronic obstructive pulmonary disease Indications and Usage: ¹⁹ ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. (1.1) Important limitations: * ARCAPTA NEOHALER is NOT indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2) * ARCAPTA NEOHALER is NOT indicated for asthma. (1.2) DrugBank Targets: ¹⁶ Beta-2 adrenergic receptor Mechanism of Action: ¹⁹ Target: beta2-adrenergic Action: agonist FDA: Indacaterol is a long-acting beta2-adrenergic agonist. When inhaled, indacaterol acts locally in the lung as a bronchodilator. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-adrenergic receptors in the human heart comprising 10%-50% of the total adrenergic receptors. The precise function of these receptors is not known, but their presence raises the possibility that even highly selective beta2- adrenergic agonists may have cardiac effects. The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3â, 5â-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3-receptors. This selectivity profile is similar to formoterol. The clinical significance of these findings is unknown.

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 726)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cytarabine

Approved, Experimental, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

147-94-4, 65-46-3

6253

Idarubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

58957-92-9

42890

Vidarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

24356-66-9

21704 32326

Fludarabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

75607-67-9, 21679-14-1

30751

Decitabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

2353-33-5

451668

Daunorubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

20830-81-3

30323

Mitoxantrone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

65271-80-9

4212

Etoposide

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

33419-42-0

36462

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

53-03-2

5865

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

135968-09-1

Benzocaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

1994-09-7, 94-09-7

2337

Sargramostim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

123774-72-1, 83869-56-1

tannic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

1401-55-4

Topotecan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

119413-54-6, 123948-87-8

60700

Amsacrine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

51264-14-3

2179

Aldesleukin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

110942-02-4, 85898-30-2

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Lenalidomide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

191732-72-6

216326

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Thiotepa

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

52-24-4

5453

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Phase 1

62-31-7, 51-61-6

681

Histamine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

51-45-6

774

Micafungin

Approved, Investigational

Phase 4,Phase 2

235114-32-6

477468 3081921

Posaconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

171228-49-2

147912

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

89594 942

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2

1406-16-2

Vitamin D3

Approved, Nutraceutical

Phase 4,Phase 2

67-97-0

5280795 6221

Calcium

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

7440-70-2

271

Calcifediol

Approved, Nutraceutical

Phase 4

19356-17-3

5283731 6433735

Ergocalciferol

Approved, Nutraceutical

Phase 4,Phase 2

50-14-6

5280793

Molgramostim

Investigational

Phase 4,Phase 3

99283-10-0

Aclarubicin

Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

57576-44-0

451415

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antiviral Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Etoposide phosphate

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Phytogenic

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interferon-alpha

Phase 4,Phase 2,Phase 1,Not Applicable

interferons

Phase 4,Phase 2,Phase 1,Not Applicable

Cyclosporins

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Gemtuzumab

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2681)

#	Name	Status	NCT ID	Phase	Drugs
1	Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia	Unknown status	NCT02277847	Phase 4	Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2	AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy	Unknown status	NCT02024308	Phase 4	Fludarabine;Cytarabine
3	Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation	Unknown status	NCT01806116	Phase 4	decitabine
4	3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia	Unknown status	NCT01587430	Phase 4	high dose ARA-C;standard dose ARA-C
5	Efficacy of G-CSF-Priming in Elderly AML Patients	Unknown status	NCT00199147	Phase 4	Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT	Unknown status	NCT02027064	Phase 4	Interferon-alpha
7	Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia	Unknown status	NCT01997372	Phase 4	ATG
8	Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）	Unknown status	NCT02218437	Phase 4	MSC+ATG
9	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)	Completed	NCT01041040	Phase 4	gemtuzumab
10	Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years	Completed	NCT00464217	Phase 4	ARA-C;Idarubicin;Leucomax
11	Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Completed	NCT00488709	Phase 4	Topotecan;Fludarabine;Cytarabine
12	Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia	Completed	NCT01819792	Phase 4
13	Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)	Active, not recruiting	NCT03026842	Phase 4	Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
14	SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia	Completed	NCT00487448	Phase 4	Fludarabine;Cytarabine;G-CSF;Idarubicin
15	AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years	Completed	NCT00180102	Phase 4	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
16	Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia	Completed	NCT01347996	Phase 4	histamine dihydrochloride and IL-2
17	Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients	Recruiting	NCT03150134	Phase 4	Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
18	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Completed	NCT01200355	Phase 4	micafungin;posaconazole
19	Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML	Recruiting	NCT02926586	Phase 4	Fludarabine;Cytarabine
20	AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients	Completed	NCT00180115	Phase 4	Cytarabine Dosage
21	LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)	Terminated	NCT01198054	Phase 4	Lenalidomide
22	Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC	Completed	NCT00180167	Phase 4	randomization between two established Chemotherapies
23	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients	Completed	NCT02267993	Phase 4	recombinant human thrombopoietin
24	Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML	Not yet recruiting	NCT03727750	Phase 4	Gemtuzumab Ozogamicin
25	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia	Completed	NCT00304447	Phase 4	Mylotarg
26	Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections	Recruiting	NCT02805946	Phase 4	posaconazole
27	King's Invasive Aspergillosis Study II	Active, not recruiting	NCT02875743	Phase 4	Posaconazole
28	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)	Completed	NCT00686543	Phase 4	Posaconazole
29	Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia	Recruiting	NCT02618109	Phase 4
30	A Rollover Study to Provide Continued Treatment With Eltrombopag	Recruiting	NCT01957176	Phase 4	ELT
31	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Recruiting	NCT02933333	Phase 4
32	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
33	A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT	Enrolling by invitation	NCT03176849	Phase 4
34	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
35	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
36	the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient	Unknown status	NCT01766375	Phase 3	Cyclosporin A,mycophenolate mofetil,Methotrexate
37	HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia	Unknown status	NCT01484171	Phase 3	idarubicin
38	Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia	Unknown status	NCT00342316	Phase 3
39	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia	Unknown status	NCT02244658	Phase 3	rhTPO
40	Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia	Unknown status	NCT02171117	Phase 3
41	Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients	Unknown status	NCT01633099	Phase 3	Decitabine
42	Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)	Unknown status	NCT01145846	Phase 3	Cytarabine plus Daunorubicin [Arm II (AD regimen)]
43	Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T	Unknown status	NCT00209833	Phase 2, Phase 3	Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
44	Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML	Unknown status	NCT02474290	Phase 2, Phase 3	Sorafenib
45	Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia	Unknown status	NCT00224614	Phase 3
46	Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study	Unknown status	NCT00715637	Phase 3	Daunorubicin and Cytarabine;Amonafide and Cytarabine
47	Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia	Unknown status	NCT00002658	Phase 3	amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
48	Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	Unknown status	NCT00003602	Phase 3	cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
49	Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents	Unknown status	NCT00111345	Phase 2, Phase 3	Anthracyclines;liposomal daunorubicin;2-CDA;AI
50	Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia	Unknown status	NCT00006045	Phase 3	cytarabine;etoposide;mitoxantrone hydrochloride

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :

cyclophosphamide

etoposide

etoposide phosphate

idarubicin

idarubicin hydrochloride

mitoxantrone

mitoxantrone hydrochloride

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Leukemia, Acute Myeloid:

	Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
	Hematopoietic stem cells for treatment of hematologic malignancies
	NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
	Peripheral blood stem cells for treatment of hematologic malignancies
	StemEx, umbilical cord blood stem/progenitor cells for hematological diseases

Embryonic/Adult Cultured Cells Related to Leukemia, Acute Myeloid:

	Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
	Bone marrow-derived hematopoietic stem cells
	Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
	Peripheral blood-derived hematopoietic stem cells (family)
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: leukemia, myeloid, acute

Sources

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

#	Genetic test	Affiliating Genes
1	Acute Myeloid Leukemia ³⁰	CBFB CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2 JAK2 KIT KRAS LPP MLF1 MLLT10 NPM1 NSD1 NUP214 PICALM RUNX1 SH3GL1 TERT

Sources

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

⁴²

Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Breast

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells	Affected by disease
2	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate

Sources

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 8195)

#	Title	Authors	Year
1	Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. ( 30954792 )	Niu P...Zhao Y	2019
2	Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values. ( 30900388 )	L?vvik Juul-Dam K...Beier Ommen H	2019
3	CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway. ( 30862962 )	Ji H...Wang Y	2019
4	Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. ( 30776582 )	Panagopoulou P...NARECHEM-ST group	2019
5	Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. ( 30550508 )	Skou AS...Nordic Society of Pediatric Hematology and Oncology (NOPHO)	2019
6	Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. ( 30898482 )	M?dry K...Dwilewicz-Trojaczek J	2019
7	Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. ( 30613922 )	Helbig G...Markiewicz M	2019
8	Multifocal muscle candidiasis of the legs in a patient with acute myeloid leukemia: A case report. ( 30813175 )	Yi P...Li L	2019
9	Rhino-orbital Mucormycosis presenting as facial cellulitis in a patient with high-risk acute myeloid leukemia in relapse. ( 30686650 )	Debureaux PE...Brissot E	2019
10	High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. ( 30022221 )	Zhang G...Fu L	2019
11	Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. ( 30718798 )	Battipaglia G...Nagler A	2019
12	Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17). ( 30899494 )	Altahan R...Khalil S	2019
13	Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia. ( 31109340 )	Giri B...Saluja A	2019
14	Cellular therapy for acute myeloid Leukemia - Current status and future prospects. ( 31109711 )	Hansrivijit P...Ciurea SO	2019
15	Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. ( 31111215 )	Forthun RB...Gjertsen BT	2019
16	Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy. ( 31111760 )	Tormo M...Navarro D	2019
17	Heterogeneity in refractory acute myeloid leukemia. ( 31064876 )	Horibata S...Hourigan CS	2019
18	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. ( 30104717 )	Lee CJ...Nagler A	2019
19	Granulocyte Colony-Stimulating Factors in Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia. ( 31070689 )	Kaplan HG...Calip GS	2019
20	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. ( 31048355 )	Poir? X...Acute Leukemia Working Party of the EBMT	2019
21	Comparisons of commonly used frontline regimens on survival outcomes in patients age 70 years and older with acute myeloid leukemia. ( 31073071 )	Talati C...Lancet JE	2019
22	Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). ( 31023346 )	Saraceni F...Nagler A	2019
23	Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. ( 30979868 )	Baron F...Nagler A	2019
24	Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. ( 30707502 )	Nomani L...Rogers HJ	2019
25	Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation. ( 30771495 )	Isobe M...Tojo A	2019
26	Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia. ( 30715157 )	Kamath GR...Taioli E	2019
27	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. ( 31000771 )	Weinberg OK...Arber DA	2019
28	Perforating Papules in a Patient With Acute Myeloid Leukemia. ( 31090880 )	Malajian D...Gallitano S	2019
29	A case of extramedullary hematopoiesis presenting as hemorrhagic panniculitis and evolving in acute myeloid leukemia. ( 31095750 )	Gallo G...Cesinaro AM	2019
30	MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia. ( 31022985 )	Bhise NS...Lamba JK	2019
31	Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. ( 31055076 )	Lin TY...Jonas BA	2019
32	Natural Products and Acute Myeloid Leukemia: A Review Highlighting Mechanisms of Action. ( 31058874 )	Hwang D...Kim B	2019
33	Outcome of Acute Myeloid Leukemia in Children Adolescents and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco. ( 30988560 )	Housou B...Quessar A	2019
34	Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. ( 31003190 )	Bhatt VR	2019
35	Clonal haematopoiesis and risk of acute myeloid leukemia. ( 31004019 )	Young AL...Druley TE	2019
36	An Atypical Chronic Ulcer Caused by Acute Myeloid Leukemia. ( 31008718 )	Semeni? D...Aleksovska N	2019
37	New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. ( 31018543 )	Bohl SR...R?cker FG	2019
38	Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction. ( 30948486 )	K?hnke T...Subklewe M	2019
39	Metabolic stress controls mutant p53 R248Q stability in acute myeloid leukemia cells. ( 30948782 )	Allende-Vega N...Villalba M	2019
40	Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. ( 30953707 )	Dellomo AJ...Rassool FV	2019
41	Homoharringtonine Combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia. ( 30953928 )	Wu Z...Xu R	2019
42	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. ( 31101526 )	Shallis RM...Zeidan AM	2019
43	Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. ( 30361416 )	Brissot E...Nagler A	2019
44	Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party. ( 30792203 )	Bazarbachi A...Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EB	2019
45	MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide. ( 30982490 )	Wang Z...Zhang M	2019
46	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. ( 31089274 )	Aldoss I...Marcucci G	2019
47	Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality. ( 31018948 )	Torkildsen S...Panagopoulos I	2019
48	Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia. ( 31050834 )	Chu Y...Yuan W	2019
49	Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion. ( 31000516 )	Plesa A...Sujobert P	2019
50	Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. ( 30922328 )	Xu ZJ...Lin J	2019

Sources

Genes for Leukemia, Acute Myeloid

Genes related to Leukemia, Acute Myeloid (38 elite genes):

(show top 50) (show all 216)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CEBPA	CCAAT Enhancer Binding Protein Alpha	Protein Coding	1725.39	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative somatic mutation ⁶⁰ Causative variation ⁷⁶ Genetic Tests ³⁰ Unconfirmed association ⁵⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	11242107 20963938 22138009 (more) 23970018 12661007 15575056 12692518
2	GATA2	GATA Binding Protein 2	Protein Coding	1425.52	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative germline mutation ⁶⁰ Genetic Tests ³⁰ Susceptibility factor ⁵⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	21670465 20040766 21765025 (more) 21242295 21892162 20963938 22138009 23970018
3	JAK2	Janus Kinase 2	Protein Coding	1306.79	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative variation ⁷⁶ Genetic Tests ³⁰ DISEASES inferred ¹⁵	16247455 20963938 22138009 (more) 23970018 15781101 15858187 15793561 16603627 16325696 18256599 20703299 25043017 25671252 17989398 19036091 16707754 16762626 19293426
4	FLT3	Fms Related Tyrosine Kinase 3	Protein Coding	1026.96	Molecular basis known ⁵⁸ Pathogenic ⁶ Genetic Tests ³⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	12384447 20963938 22138009 (more) 23970018 11290608 14670924 11442493
5	NPM1	Nucleophosmin 1	Protein Coding	1019.2	Molecular basis known ⁵⁸ Pathogenic ⁶ Genetic Tests ³⁰ DISEASES inferred ¹⁵	15659725 20963938 22138009 (more) 23970018
6	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	1007.95	Molecular basis known ⁵⁸ Pathogenic/Likely pathogenic ⁶ Genetic Tests ³⁰ DISEASES inferred ¹⁵	7513208 9657776 8589724 (more) 19865100 20963938 22138009 23970018
	KIT::MIR221 ⁴⁸	MIR221 Macro RNA (hsa-miR-221) targets KIT
	KIT::MIR222 ⁴⁸	MIR222 Macro RNA (hsa-miR-222) targets KIT
7	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	1007.94	Molecular basis known ⁵⁸ Pathogenic ⁶ Genetic Tests ³⁰ DISEASES inferred ¹⁵	20963938 22138009 23970018 (more) 28941052 21067377
8	ETV6	ETS Variant 6	Protein Coding	1006.54	Molecular basis known ⁵⁸ Pathogenic ⁶ Genetic Tests ³⁰ DISEASES inferred ¹⁵	15806161 20963938 22138009 (more) 23970018
9	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1004.6	Molecular basis known ⁵⁸ Pathogenic ⁶ Genetic Tests ³⁰ DISEASES inferred ¹⁵	8955068 20963938 22138009 (more) 23970018
10	TGM6	Transglutaminase 6	Protein Coding	750	Pathogenic ⁶ Causative germline mutation ⁶⁰	20963938 22138009 23970018
11	TERT	Telomerase Reverse Transcriptase	Protein Coding	697.15	Molecular basis known ⁵⁸ Genetic Tests ³⁰ Susceptibility factor ⁵⁸ Risk factor ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018 (more) 20301779 19147845
12	CHIC2	Cysteine Rich Hydrophobic Domain 2	Protein Coding	653.29	Molecular basis known ⁵⁸ Genetic Tests ³⁰ Susceptibility factor ⁵⁸ DISEASES inferred ¹⁵
13	RUNX1	RUNX Family Transcription Factor 1	Protein Coding	632.91	Molecular basis known ⁵⁸ Genetic Tests ³⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
14	PICALM	Phosphatidylinositol Binding Clathrin Assembly Protein	Protein Coding	621.96	Molecular basis known ⁵⁸ Genetic Tests ³⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Summaries (show sections)
15	MLLT10	MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor	Protein Coding	606.74	Molecular basis known ⁵⁸ Genetic Tests ³⁰ DISEASES inferred ¹⁵
16	NUP214	Nucleoporin 214	Protein Coding	606.07	Molecular basis known ⁵⁸ Genetic Tests ³⁰ DISEASES inferred ¹⁵
17	LPP	LIM Domain Containing Preferred Translocation Partner In Lipoma	Protein Coding	600	Molecular basis known ⁵⁸ Genetic Tests ³⁰
18	NSD1	Nuclear Receptor Binding SET Domain Protein 1	Protein Coding	555.81	Pathogenic/Likely pathogenic ⁶ Genetic Tests ³⁰ Genetic association ⁵⁸ DISEASES inferred ¹⁵
19	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	424.68	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018
20	CSF3R	Colony Stimulating Factor 3 Receptor	Protein Coding	424.32	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018
21	PTPN11	Protein Tyrosine Phosphatase Non-Receptor Type 11	Protein Coding	423.75	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018
22	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial	Protein Coding	407.69	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
23	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic	Protein Coding	407.67	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
24	TP53	Tumor Protein P53	Protein Coding	406.81	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
25	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	406.48	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
26	DNAJC21	DnaJ Heat Shock Protein Family (Hsp40) Member C21	Protein Coding	403.93	Pathogenic ⁶ DISEASES inferred ¹⁵
27	DDX41	DEAD-Box Helicase 41	Protein Coding	403.9	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
28	SF3B1	Splicing Factor 3b Subunit 1	Protein Coding	400	Pathogenic ⁶	20963938 22138009 23970018
29	KMT2A	Lysine Methyltransferase 2A	Protein Coding	373.51	Gene fusion ⁶⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
30	TET2	Tet Methylcytosine Dioxygenase 2	Protein Coding	357.58	Causative somatic mutation ⁶⁰ DISEASES inferred ¹⁵
31	MIR126	MicroRNA 126	RNA Gene	350	Causal ⁴⁸	18832181
32	MIR320A	MicroRNA 320a	RNA Gene	350	Causal ⁴⁸	19135902
33	MIR204	MicroRNA 204	RNA Gene	350	Causal ⁴⁸	18308931
34	MIR34B	MicroRNA 34b	RNA Gene	350	Causal ⁴⁸	19258499
35	SETBP1	SET Binding Protein 1	Protein Coding	304.62	Causative variation ⁷⁶ DISEASES inferred ¹⁵
36	MLF1	Myeloid Leukemia Factor 1	Protein Coding	156.02	Genetic Tests ³⁰ Genetic association ⁵⁸ DISEASES inferred ¹⁵
37	SH3GL1	SH3 Domain Containing GRB2 Like 1, Endophilin A2	Protein Coding	154.76	Genetic Tests ³⁰ Genetic association ⁵⁸ DISEASES inferred ¹⁵
38	CBFB	Core-Binding Factor Subunit Beta	Protein Coding	154.61	Genetic Tests ³⁰ Genetic association ⁵⁸ DISEASES inferred ¹⁵
39	IRAIN	IGF1R Antisense Imprinted Non-Protein Coding RNA	RNA Gene	154.16	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵	25092925
40	HOTAIRM1	HOXA Transcript Antisense RNA, Myeloid-Specific 1	RNA Gene	154.02	Experimental evidence: Locus ⁴⁰ DISEASES inferred ¹⁵	26436590
41	CCDC26	CCDC26 Long Non-Coding RNA	RNA Gene	153.95	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵	25928165
42	WT1-AS	WT1 Antisense RNA	RNA Gene	153.01	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵	17940140 10340388
43	TUG1	Taurine Up-Regulated 1	RNA Gene	153	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	29654398
44	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	21414664 18185590
45	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Expression ⁴⁰	28669171 26622861 26261618 (more) 25979172
46	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	26923190
47	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Expression ⁴⁰	28713913
48	MEG3	Maternally Expressed 3	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	19595458
49	TUSC7	Tumor Suppressor Candidate 7	RNA Gene	150	Experimental evidence: Expression ⁴⁰	26345353
50	UCA1	Urothelial Cancer Associated 1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	26053097

Sources

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

⁷⁶

#	Symbol	AA change	Variation ID	SNP ID
1	CEBPA	p.His84Leu	VAR_072677	rs28931590
2	JAK2	p.Lys607Asn	VAR_032696	rs121912472
3	JAK2	p.Val617Phe	VAR_032697	rs77375493
4	SETBP1	p.Gly870Ser	VAR_063809	rs267607040
5	SETBP1	p.Ser854Ala	VAR_069848
6	SETBP1	p.Gly870Arg	VAR_069854
7	SETBP1	p.Ile871Ser	VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

⁶ (show top 50) (show all 853)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	CEBPA	NM_004364.4(CEBPA): c.1021A> G (p.Ile341Val)	single nucleotide variant	Uncertain significance	rs372931505	GRCh37	Chromosome 19, 33792300: 33792300
2	CEBPA	NM_004364.4(CEBPA): c.1021A> G (p.Ile341Val)	single nucleotide variant	Uncertain significance	rs372931505	GRCh38	Chromosome 19, 33301394: 33301394
3	CEBPA	NM_004364.4(CEBPA): c.1018G> A (p.Gly340Ser)	single nucleotide variant	Uncertain significance	rs375833261	GRCh38	Chromosome 19, 33301397: 33301397
4	CEBPA	NM_004364.4(CEBPA): c.1018G> A (p.Gly340Ser)	single nucleotide variant	Uncertain significance	rs375833261	GRCh37	Chromosome 19, 33792303: 33792303
5	CEBPA	NM_004364.4(CEBPA): c.724G> A (p.Gly242Ser)	single nucleotide variant	Uncertain significance	rs530569305	GRCh38	Chromosome 19, 33301691: 33301691
6	CEBPA	NM_004364.4(CEBPA): c.724G> A (p.Gly242Ser)	single nucleotide variant	Uncertain significance	rs530569305	GRCh37	Chromosome 19, 33792597: 33792597
7	CEBPA	NM_004364.4(CEBPA): c.667G> A (p.Gly223Ser)	single nucleotide variant	Uncertain significance	rs535980233	GRCh38	Chromosome 19, 33301748: 33301748
8	CEBPA	NM_004364.4(CEBPA): c.667G> A (p.Gly223Ser)	single nucleotide variant	Uncertain significance	rs535980233	GRCh37	Chromosome 19, 33792654: 33792654
9	CEBPA	NM_004364.4(CEBPA): c.576G> A (p.Pro192=)	single nucleotide variant	Likely benign	rs878854703	GRCh37	Chromosome 19, 33792745: 33792745
10	FLT3	NM_004119.2(FLT3): c.1715A> G (p.Tyr572Cys)	single nucleotide variant	Likely pathogenic	rs121913491	GRCh38	Chromosome 13, 28034204: 28034204
11	FLT3	NM_004119.2(FLT3): c.1715A> G (p.Tyr572Cys)	single nucleotide variant	Likely pathogenic	rs121913491	GRCh37	Chromosome 13, 28608341: 28608341
12	FLT3	NM_004119.2(FLT3): c.2506_2508delATC (p.Ile836del)	deletion	Likely pathogenic	rs121913490	GRCh38	Chromosome 13, 28018500: 28018502
13	HRAS; LRRC56	NM_005343.3(HRAS): c.182A> C (p.Gln61Pro)	single nucleotide variant	Likely pathogenic	rs121913233	GRCh38	Chromosome 11, 533874: 533874
14	HRAS; LRRC56	NM_005343.3(HRAS): c.182A> C (p.Gln61Pro)	single nucleotide variant	Likely pathogenic	rs121913233	GRCh37	Chromosome 11, 533874: 533874
15	FLT3	NM_004119.2(FLT3): c.2506_2508delATC (p.Ile836del)	deletion	Likely pathogenic	rs121913490	GRCh37	Chromosome 13, 28592637: 28592639
16	FLT3	NM_004119.2(FLT3): c.1855G> T (p.Gly619Cys)	single nucleotide variant	Likely pathogenic	rs1057519769	GRCh38	Chromosome 13, 28033974: 28033974
17	FLT3	NM_004119.2(FLT3): c.1855G> T (p.Gly619Cys)	single nucleotide variant	Likely pathogenic	rs1057519769	GRCh37	Chromosome 13, 28608111: 28608111
18	FLT3	NM_004119.2(FLT3): c.1952A> G (p.Asp651Gly)	single nucleotide variant	Likely pathogenic	rs1057519768	GRCh38	Chromosome 13, 28028279: 28028279
19	FLT3	NM_004119.2(FLT3): c.1952A> G (p.Asp651Gly)	single nucleotide variant	Likely pathogenic	rs1057519768	GRCh37	Chromosome 13, 28602416: 28602416
20	FLT3	NM_004119.2(FLT3): c.2026A> G (p.Asn676Asp)	single nucleotide variant	Likely pathogenic	rs1057519767	GRCh38	Chromosome 13, 28028205: 28028205
21	FLT3	NM_004119.2(FLT3): c.2026A> G (p.Asn676Asp)	single nucleotide variant	Likely pathogenic	rs1057519767	GRCh37	Chromosome 13, 28602342: 28602342
22	FLT3	NM_004119.2(FLT3): c.2028C> A (p.Asn676Lys)	single nucleotide variant	Likely pathogenic	rs1057519766	GRCh38	Chromosome 13, 28028203: 28028203
23	FLT3	NM_004119.2(FLT3): c.2028C> A (p.Asn676Lys)	single nucleotide variant	Likely pathogenic	rs1057519766	GRCh37	Chromosome 13, 28602340: 28602340
24	FLT3	NM_004119.2(FLT3): c.2028C> G (p.Asn676Lys)	single nucleotide variant	Likely pathogenic	rs1057519766	GRCh38	Chromosome 13, 28028203: 28028203
25	FLT3	NM_004119.2(FLT3): c.2028C> G (p.Asn676Lys)	single nucleotide variant	Likely pathogenic	rs1057519766	GRCh37	Chromosome 13, 28602340: 28602340
26	FLT3	NM_004119.2(FLT3): c.2059A> T (p.Ile687Phe)	single nucleotide variant	Likely pathogenic	rs1057519765	GRCh38	Chromosome 13, 28027236: 28027236
27	FLT3	NM_004119.2(FLT3): c.2059A> T (p.Ile687Phe)	single nucleotide variant	Likely pathogenic	rs1057519765	GRCh37	Chromosome 13, 28601373: 28601373
28	FLT3	NM_004119.2(FLT3): c.2073T> A (p.Phe691Leu)	single nucleotide variant	Likely pathogenic	rs1057519764	GRCh38	Chromosome 13, 28027222: 28027222
29	FLT3	NM_004119.2(FLT3): c.2073T> A (p.Phe691Leu)	single nucleotide variant	Likely pathogenic	rs1057519764	GRCh37	Chromosome 13, 28601359: 28601359
30	FLT3	NM_004119.2(FLT3): c.2073T> G (p.Phe691Leu)	single nucleotide variant	Likely pathogenic	rs1057519764	GRCh38	Chromosome 13, 28027222: 28027222
31	FLT3	NM_004119.2(FLT3): c.2073T> G (p.Phe691Leu)	single nucleotide variant	Likely pathogenic	rs1057519764	GRCh37	Chromosome 13, 28601359: 28601359
32	FLT3	NM_004119.2(FLT3): c.2503_2504delGAinsTT (p.Asp835Phe)	indel	Likely pathogenic	rs1057519763	GRCh38	Chromosome 13, 28018504: 28018505
33	FLT3	NM_004119.2(FLT3): c.2503_2504delGAinsTT (p.Asp835Phe)	indel	Likely pathogenic	rs1057519763	GRCh37	Chromosome 13, 28592641: 28592642
34	FLT3	NM_004119.2(FLT3): c.2524T> C (p.Tyr842His)	single nucleotide variant	Likely pathogenic	rs1057519762	GRCh38	Chromosome 13, 28018484: 28018484
35	FLT3	NM_004119.2(FLT3): c.2524T> C (p.Tyr842His)	single nucleotide variant	Likely pathogenic	rs1057519762	GRCh37	Chromosome 13, 28592621: 28592621
36	FLT3	NM_004119.2(FLT3): c.2525A> G (p.Tyr842Cys)	single nucleotide variant	Likely pathogenic	rs376588714	GRCh38	Chromosome 13, 28018483: 28018483
37	FLT3	NM_004119.2(FLT3): c.2525A> G (p.Tyr842Cys)	single nucleotide variant	Likely pathogenic	rs376588714	GRCh37	Chromosome 13, 28592620: 28592620
38	SF3B1	NM_012433.3(SF3B1): c.2098A> C (p.Lys700Gln)	single nucleotide variant	Likely pathogenic	rs559063155	GRCh38	Chromosome 2, 197402110: 197402110
39	SF3B1	NM_012433.3(SF3B1): c.2098A> C (p.Lys700Gln)	single nucleotide variant	Likely pathogenic	rs559063155	GRCh37	Chromosome 2, 198266834: 198266834
40	SF3B1	NM_012433.3(SF3B1): c.2098A> T (p.Lys700Ter)	single nucleotide variant	Likely pathogenic	rs559063155	GRCh38	Chromosome 2, 197402110: 197402110
41	SF3B1	NM_012433.3(SF3B1): c.2098A> T (p.Lys700Ter)	single nucleotide variant	Likely pathogenic	rs559063155	GRCh37	Chromosome 2, 198266834: 198266834
42	SF3B1	NM_012433.3(SF3B1): c.2099A> C (p.Lys700Thr)	single nucleotide variant	Likely pathogenic	rs1057519756	GRCh38	Chromosome 2, 197402109: 197402109
43	SF3B1	NM_012433.3(SF3B1): c.2099A> C (p.Lys700Thr)	single nucleotide variant	Likely pathogenic	rs1057519756	GRCh37	Chromosome 2, 198266833: 198266833
44	SF3B1	NM_012433.3(SF3B1): c.2099A> G (p.Lys700Arg)	single nucleotide variant	Likely pathogenic	rs1057519756	GRCh38	Chromosome 2, 197402109: 197402109
45	SF3B1	NM_012433.3(SF3B1): c.2099A> G (p.Lys700Arg)	single nucleotide variant	Likely pathogenic	rs1057519756	GRCh37	Chromosome 2, 198266833: 198266833
46	SF3B1	NM_012433.3(SF3B1): c.2099A> T (p.Lys700Ile)	single nucleotide variant	Likely pathogenic	rs1057519756	GRCh38	Chromosome 2, 197402109: 197402109
47	SF3B1	NM_012433.3(SF3B1): c.2099A> T (p.Lys700Ile)	single nucleotide variant	Likely pathogenic	rs1057519756	GRCh37	Chromosome 2, 198266833: 198266833
48	SF3B1	NM_012433.3(SF3B1): c.2100A> C (p.Lys700Asn)	single nucleotide variant	Likely pathogenic	rs1057519755	GRCh38	Chromosome 2, 197402108: 197402108
49	SF3B1	NM_012433.3(SF3B1): c.2100A> C (p.Lys700Asn)	single nucleotide variant	Likely pathogenic	rs1057519755	GRCh37	Chromosome 2, 198266832: 198266832
50	SF3B1	NM_012433.3(SF3B1): c.2100A> T (p.Lys700Asn)	single nucleotide variant	Likely pathogenic	rs1057519755	GRCh38	Chromosome 2, 197402108: 197402108

Copy number variations for Leukemia, Acute Myeloid from CNVD:

⁷ (show top 50) (show all 491)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	232758	8	119200000	127300000	Insertion	MYC	Acute myeloid leukemia
2	232759	8	119200000	127300000	Insertion	NSE2	Acute myeloid leukemia
3	232760	8	119200000	127300000	Insertion	TRIB1	Acute myeloid leukemia
4	232757	8	119200000	127300000	Insertion	FLJ32440	Acute myeloid leukemia
5	232756	8	119200000	127300000	Insertion	C8FW	Acute myeloid leukemia
6	232517	8	117700000	119200000	Deletion		Acute myeloid leukemia
7	231360	8	104000	47043000	Gain		Acute myeloid leukemia
8	230513	7	99529552	99529633	Deletion		Acute myeloid leukemia
9	230511	7	99529327	99529406	Deletion	miR-93	Acute myeloid leukemia
10	230509	7	99529119	99529202	Deletion	miR-25	Acute myeloid leukemia
11	229606	7	92302000	156450000	Loss		Acute myeloid leukemia
12	229568	7	92068000	92292000	Gain		Acute myeloid leukemia
13	229366	7	90633327	119508217	Deletion		Acute myeloid leukemia
14	228440	7	76108000	158812000	Gain or loss		Acute myeloid leukemia
15	208359	6	168087000	169485000	Gain		Acute myeloid leukemia
16	208073	6	164500000	171115067	Copy number	MLLT4	Acute myeloid leukemia
17	206240	6	137855022	140711307	Duplication		Acute myeloid leukemia
18	206076	6	135555189	135763913	Gain	MYB	Acute myeloid leukemia
19	206075	6	135555189	135763913	Gain	AHI1	Acute myeloid leukemia
20	204737	6	114621527	115238795	Loss		Acute myeloid leukemia
21	204410	6	110000	42427000	Gain		Acute myeloid leukemia
22	203935	6	104200000	106000000	Gain		Acute myeloid leukemia
23	203875	6	1033000	27766000	Loss		Acute myeloid leukemia
24	203701	6	1	60500000	Insertion	TNF	Acute myeloid leukemia
25	203700	6	1	60500000	Insertion	PBX2	Acute myeloid leukemia
26	203321	5	97054000	101265000	Gain		Acute myeloid leukemia
27	203276	5	96271209	168210016	Deletion		Acute myeloid leukemia
28	175189	3	37985899	37985975	Deletion		Acute myeloid leukemia
29	174928	3	35760972	35761055	Deletion		Acute myeloid leukemia
30	174461	3	26371277	81284264	Deletion		Acute myeloid leukemia
31	173099	3	189889263	189889348	Deletion	miR-28	Acute myeloid leukemia
32	172501	3	182993000	199318000	Gain		Acute myeloid leukemia
33	172485	3	182700000	187900000	Deletion		Acute myeloid leukemia
34	172407	3	18124000	50667000	Loss		Acute myeloid leukemia
35	172263	3	179722000	179941000	Loss		Acute myeloid leukemia
36	171585	3	170129000	199318000	Gain		Acute myeloid leukemia
37	171169	3	163995351	164109297	Gain		Acute myeloid leukemia
38	170926	3	161605227	161605307	Deletion		Acute myeloid leukemia
39	170923	3	161605070	161605167	Deletion	miR-15b	Acute myeloid leukemia
40	169892	3	148103000	199318000	Gain or loss		Acute myeloid leukemia
41	168151	3	127549061	128880998	Deletion		Acute myeloid leukemia
42	166190	3	1	95713000	Gain or loss		Acute myeloid leukemia
43	166151	3	1	91700000	Deletion	MLH1	Acute myeloid leukemia
44	166124	3	1	80807000	Gain or loss		Acute myeloid leukemia
45	166109	3	1	54393000	Gain or loss		Acute myeloid leukemia
46	165626	22	47354576	49468408	Amplification		Acute myeloid leukemia
47	165625	22	47354576	49468408	Amplification		Acute myeloid leukemia
48	165438	22	44927000	49560000	Gain		Acute myeloid leukemia
49	165336	22	44003066	49202107	Deletion		Acute myeloid leukemia
50	164829	22	39818559	39906027	Translate	EP300	Acute myeloid leukemia

Sources

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Sources

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

³⁸

#	Name	Kegg Source Accession
1	Acute myeloid leukemia	hsa05221
2	Transcriptional misregulation in cancer	hsa05202

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 22)

#	Super pathways	Score	Top Affiliating Genes
1	Akt Signaling ⁶⁵ Show member pathways p38 Signaling ⁶⁵ Tec Kinases Signaling ⁶⁵	13.27	CEBPA CSF3R FLT3 JAK2 KIT KRAS
2	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.2	CSF3R FLT3 JAK2 KIT KRAS NRAS
3	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.64	CSF3R FLT3 JAK2 KIT KRAS NRAS
4	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.63	CEBPA FLT3 KIT KRAS NRAS RUNX1
5	NF-kappaB Signaling ⁴	12.35	CEBPA GATA2 JAK2 KIT RUNX1
6	JAK-STAT signaling pathway (KEGG) ⁶⁶ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁷ JAK-STAT signaling pathway ³⁸	12.26	CSF3R JAK2 KRAS NRAS
7	CNTF Signaling ⁶⁵ Show member pathways FLT3 Signaling ⁶⁵ IL-3 Pathway ⁶⁵ Nur77-Induced AICD in Macrophage ⁶⁵ OSM Pathway ⁶⁵	12.16	FLT3 JAK2 KRAS NRAS
8	Transcriptional misregulation in cancer ³⁸	12.05	CEBPA ETV6 FLT3 RUNX1
9	Pathways in cancer ³⁸	12	CEBPA CSF3R FLT3 JAK2 KIT KRAS
10	Tyrosine Kinases / Adaptors ⁴	11.93	FLT3 JAK2 KIT NPM1
11	Signaling by ERBB4 ⁶⁷ Show member pathways Downregulation of ERBB4 signaling ⁶⁷ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁷	11.81	JAK2 KRAS NRAS
12	AGE-RAGE signaling pathway in diabetic complications ³⁸	11.77	JAK2 KRAS NRAS
13	Hematopoietic cell lineage ³⁸	11.75	CSF3R FLT3 KIT
14	Jak-Stat Signaling Pathway (sino) ⁶⁸	11.61	CSF3R JAK2 KRAS NRAS
15	C-MYB transcription factor network ¹	11.6	CEBPA KIT NRAS
16	HIF-1-alpha transcription factor network ¹	11.5	GATA2 NPM1 TERT
17	Negative regulation of MAPK pathway ⁶⁷ Show member pathways RAF activation ⁶⁷	11.48	JAK2 KRAS NRAS
18	VEGF Pathway (Tocris) ⁶² Show member pathways VEGF Pathway ⁷³	11.38	FLT3 KIT KRAS NRAS
19	Transcription_Transcription factor Tubby signaling pathways ²³	11.16	JAK2 KRAS NRAS
20	Central carbon metabolism in cancer ³⁸	11.07	FLT3 KIT KRAS NRAS
21	Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex ¹	10.84	DNMT3A ETV6 FLT3
22	p38MAPK events ⁶⁷	10.67	KRAS NRAS

Sources

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	9.85	CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2	nucleus	GO:0005634	9.8	CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
3	focal adhesion	GO:0005925	9.02	JAK2 KRAS LPP NPM1 NUP214

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell proliferation	GO:0008284	9.91	FLT3 JAK2 KIT KRAS NPM1
2	negative regulation of transcription by RNA polymerase II	GO:0000122	9.91	CEBPA DNMT3A ETV6 GATA2 NSD1 RUNX1
3	negative regulation of gene expression	GO:0010629	9.78	GATA2 PICALM RUNX1 TERT
4	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.58	FLT3 JAK2 KIT
5	MAPK cascade	GO:0000165	9.55	FLT3 JAK2 KIT KRAS NRAS
6	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.54	FLT3 JAK2 KIT
7	positive regulation of MAP kinase activity	GO:0043406	9.5	FLT3 KIT KRAS
8	hematopoietic stem cell proliferation	GO:0071425	9.49	ETV6 RUNX1
9	regulation of myeloid cell differentiation	GO:0045637	9.46	CSF3R RUNX1
10	cytokine-mediated signaling pathway	GO:0019221	9.43	CEBPA CSF3R FLT3 JAK2 KIT KRAS
11	myeloid progenitor cell differentiation	GO:0002318	9.26	FLT3 KIT
12	hemopoiesis	GO:0030097	9.02	RUNX1 PICALM FLT3 GATA2 KIT

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin binding	GO:0003682	9.65	DNMT3A GATA2 MLLT10 NPM1 NSD1
2	protein binding	GO:0005515	9.6	CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
3	nucleotide binding	GO:0000166	9.55	FLT3 JAK2 KIT KRAS NRAS
4	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.43	CEBPA DNMT3A ETV6 GATA2 NSD1 RUNX1

Sources

Sources for Leukemia, Acute Myeloid

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia

Leukemia, Acute Myeloid (AML)

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Characteristics:

Orphanet epidemiological data:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Leukemia, Acute Myeloid

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Human phenotypes related to Leukemia, Acute Myeloid:

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

UMLS symptoms related to Leukemia, Acute Myeloid:

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 74 / NDF-RT 52 :

Cell-based therapeutics:

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

Genes for Leukemia, Acute Myeloid

Genes related to Leukemia, Acute Myeloid (38 elite genes):

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

Copy number variations for Leukemia, Acute Myeloid from CNVD:

Expression for Leukemia, Acute Myeloid

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Sources for Leukemia, Acute Myeloid

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :